Can I Take Creatine With Prolia (Denosumab)?

How Denosumab (Prolia) Works and Why Kidneys Matter

Denosumab is a fully human monoclonal antibody that binds and neutralizes RANK ligand (RANKL), the signaling protein that drives osteoclast formation, function, and survival. By blocking RANKL, denosumab reduces bone resorption and increases bone mineral density (BMD). The key FREEDOM trial (N=7,868) showed a 68% reduction in new vertebral fractures and a 40% reduction in hip fractures over 36 months in postmenopausal women with osteoporosis [1].

Denosumab Elimination Does Not Involve the Kidneys

Unlike bisphosphonates, denosumab is eliminated through the reticuloendothelial system, not renal clearance. No dose adjustment is required purely on the basis of reduced kidney function [2]. This is a meaningful distinction: the drug itself will not accumulate in patients with low eGFR the way alendronate would.

Why Renal Function Still Needs Monitoring

Despite the non-renal elimination route, the Prolia prescribing information explicitly flags hypocalcemia as a serious adverse event, and the risk of hypocalcemia is substantially higher when vitamin D and calcium stores are low, which is common in patients with chronic kidney disease (CKD) [2]. The FDA label states: "Hypocalcemia must be corrected prior to initiating Prolia. Monitor calcium levels and adequately supplement all patients with calcium and vitamin D" [2]. Clinicians therefore routinely check a comprehensive metabolic panel (CMP) before each injection, and any unexplained creatinine rise will prompt a nephrology review or delay of the next dose.

What Creatine Does to Serum Creatinine

Creatine phosphate stored in muscle is irreversibly converted to creatinine at a rate proportional to total creatine pool size. Adding exogenous creatine expands that pool, which increases daily creatinine production and raises serum creatinine even when true GFR is unchanged [3].

Magnitude of the Creatinine Rise

A crossover study by Pline and Smith (Pharmacotherapy, 2005) found that creatine monohydrate 5 g/day for 28 days raised serum creatinine by a mean of 0.24 mg/dL (approximately 21%) above baseline in healthy adults, without any change in cystatin C-based GFR [3]. Because cystatin C is not derived from muscle metabolism, it is unaffected by creatine loading. This dissociation between creatinine and cystatin C is the biochemical fingerprint of creatine-induced pseudocreatininemia.

CKD-EPI and MDRD Equations Are Affected

Both the CKD-EPI and MDRD equations use serum creatinine as their primary input. A 0.24 mg/dL rise in a patient whose baseline creatinine is 0.9 mg/dL could drop the calculated eGFR from roughly 75 mL/min to roughly 60 mL/min on paper, pushing that patient from CKD stage 2 into stage 3a without any real change in kidney function [4]. For a Prolia patient whose clinician is watching for a threshold of eGFR <30, a spurious 15-point drop is clinically meaningful and could delay a bone-protective injection unnecessarily.

Cystatin C as the Corrective Test

A 2012 meta-analysis in the American Journal of Kidney Diseases (Inker et al., N=5,352) showed that cystatin C-based eGFR equations are significantly more accurate than creatinine-based equations when muscle mass or diet confounds creatinine [4]. If your creatinine rises after starting creatine, requesting a cystatin C test from your clinician is a straightforward way to confirm that true GFR is stable.

Does Creatine Offer Bone-Related Benefits Alongside Prolia?

This is where the conversation gets more clinically interesting. Denosumab reduces resorption; it does not directly stimulate bone formation. Resistance exercise stimulates osteoblast activity and adds to BMD gains that denosumab alone cannot match [5].

Creatine, Exercise, and Bone Mineral Density

A randomized controlled trial by Chilibeck et al. (Medicine and Science in Sports and Exercise, 2015, N=47 postmenopausal women) found that creatine supplementation (0.1 g/kg/day) combined with resistance training produced significantly greater gains in femoral neck BMD compared to placebo plus resistance training over 52 weeks (P<0.05) [5]. A subsequent systematic review and meta-analysis by Candow et al. In the Journal of Clinical Medicine (2021) confirmed that creatine combined with resistance training improves bone geometry and lean mass in older adults [6].

Mechanism: Creatine Augments Osteogenic Loading

Creatine raises intramuscular phosphocreatine, allowing greater power output during resistance training. Greater mechanical loading on bone from stronger muscle contractions is the proposed mechanism for the BMD benefit [6]. Denosumab's anti-resorptive effect and creatine-augmented mechanical loading target different pathways, which means their bone effects may complement each other rather than overlap.

What the Data Do Not Show Yet

No published RCT has enrolled patients on denosumab who were simultaneously taking creatine and tracked fracture incidence as a primary endpoint. The bone-benefit evidence for creatine is promising but confined to exercise-plus-supplement trials in populations not necessarily on antiresorptive therapy. Patients should treat any claimed synergistic effect as hypothesis-generating, not established.

Practical Decision Framework: Should You Take Creatine With Prolia?

The answer depends on three clinical variables: your current eGFR, your calcium status, and your ability to get timely lab work.

Step 1: Establish a Baseline Before Starting Creatine

Request a CMP and a cystatin C level from your prescriber before your first dose of creatine. This gives your clinical team a documented pre-creatine creatinine value to compare against future labs. Without this baseline, a rise in creatinine six months later will be impossible to attribute confidently to creatine versus genuine GFR decline.

Step 2: Time Labs Carefully Around Injections

Prolia injections happen every six months. Many clinicians draw a CMP one to two weeks before the injection date to confirm calcium and kidney function. If you are taking creatine, flag this to your prescriber at least four weeks before the scheduled injection so they can order both creatinine and cystatin C. This prevents a creatine-driven creatinine blip from triggering an unnecessary injection delay.

Step 3: Use Maintenance Dosing, Not Loading Protocols

A standard creatine loading protocol (20 g/day for 5 to 7 days) saturates the muscle creatine pool rapidly and produces the sharpest short-term creatinine spike. If you are on Prolia, consider skipping the loading phase and starting directly at 3 to 5 g/day maintenance. A trial by Greenhaff et al. (Clinical Science, 1994) confirmed that 3 g/day for 28 days achieves full muscle saturation without the acute creatinine surge of a loading dose [7].

Step 4: Patients With eGFR <30 Should Discuss With a Nephrologist First

For patients already in CKD stage 4 (eGFR 15 to 29 mL/min/1.73 m²) or stage 5, adding creatine is not automatically safe. Denosumab-related hypocalcemia risk is already elevated in this group [2], and any further confusion of renal-function markers adds diagnostic noise at a moment when precision matters. The 2022 KDIGO guidelines on CKD-mineral and bone disorder recommend individualized antiresorptive decisions in patients with eGFR <30 [8].

Hypocalcemia: A Separate Concern Worth Separating

Creatine does not affect serum calcium, ionized calcium, or parathyroid hormone (PTH). The hypocalcemia risk with Prolia is driven by its potent suppression of bone resorption, which acutely reduces the calcium flux from bone into blood. A 2014 analysis published in the Journal of Bone and Mineral Research (Cummings et al.) found that hypocalcemia occurred in approximately 2% of patients in the FREEDOM extension study, predominantly in those with vitamin D insufficiency [9].

What Patients Should Monitor for Hypocalcemia

Symptoms of hypocalcemia include perioral tingling, muscle cramps, and in severe cases, carpopedal spasm or cardiac arrhythmia. Serum calcium should be checked within two to four weeks after each Prolia injection in higher-risk patients. Creatine supplementation does not change this requirement or this timeline.

Vitamin D and Calcium Supplementation Are Mandatory

The FDA-approved prescribing label requires that all patients on Prolia receive at least 1,000 mg elemental calcium and 400 IU vitamin D daily [2]. Many osteoporosis guidelines recommend 800 to 2,000 IU vitamin D3 to maintain a 25-hydroxyvitamin D level above 30 ng/mL. This supplementation requirement exists independent of any decision about creatine.

Creatine Safety Profile in Older Adults

Creatine has one of the most extensively studied safety records of any sports supplement. A position statement from the International Society of Sports Nutrition (Kreider et al., Journal of the International Society of Sports Nutrition, 2017) concluded that creatine monohydrate at 3 to 5 g/day is safe for long-term use in healthy adults across age groups, with no evidence of adverse effects on kidney function in people with normal baseline renal health [10].

The Exception: Pre-Existing Renal Disease

That same ISSN position statement explicitly noted that creatine has not been adequately studied in people with pre-existing renal impairment and that caution is warranted in that population [10]. For Prolia patients with CKD stage 1 to 3 and stable, normal-range creatinine, the available evidence supports short-term safety. For those with CKD stage 4 to 5, the evidence base is thin.

Creatine Formulation Matters

Creatine monohydrate is the form used in virtually every published clinical trial. Creatine ethyl ester, buffered creatine, and creatine hydrochloride lack the same evidence base and in some analyses have shown faster conversion to the inactive metabolite creatinine in the GI tract, potentially amplifying the creatinine elevation without the muscle-loading benefit [10]. Prolia patients who choose to supplement should use creatine monohydrate.

Drug-Drug and Drug-Supplement Interactions With Denosumab

Denosumab has no known clinically significant pharmacokinetic interactions with other drugs or supplements because it does not use cytochrome P450 enzymes, P-glycoprotein, or renal transport systems [2]. This is confirmed in the FDA prescribing information, which lists no formal drug-drug interaction contraindications aside from other bone-active agents used simultaneously.

Supplements to Avoid or Monitor Separately

While creatine's interaction is indirect, a few other supplements do carry more direct concerns alongside Prolia:

• High-dose vitamin A (retinol) above 10,000 IU/day can accelerate bone resorption and partially counteract denosumab's effect on osteoclast suppression, as noted in a review by Johansson and Melhus in the New England Journal of Medicine (2002) [11].
• St. John's Wort may alter immune regulation, though no specific RANKL-pathway interaction has been documented in primary literature to date.
• Calcium and vitamin D supplements are not just compatible with Prolia but are mandatory per the FDA label [2].

Monitoring Schedule Summary

A straightforward monitoring plan integrates creatine use into the standard Prolia follow-up without requiring extra clinic visits in most cases.

| Timepoint | Labs to Order | Why | |---|---|---| | Before starting creatine | CMP + cystatin C | Establish true baseline GFR | | 4 to 8 weeks after starting creatine | Serum creatinine + cystatin C | Confirm no true GFR decline | | 2 to 4 weeks before each Prolia injection | CMP (calcium, creatinine) | Standard pre-injection check | | 2 to 4 weeks after each Prolia injection | Serum calcium | Hypocalcemia surveillance |

If cystatin C-based eGFR is stable while creatinine-based eGFR has fallen, the creatinine rise is attributable to creatine and the injection should proceed on schedule [4].

Talking to Your Prescriber

Bring the following specifics to your next appointment:

• The brand and form of creatine you plan to take (creatine monohydrate, 3 to 5 g/day)
• Your most recent creatinine, eGFR, and calcium values
• The date of your next scheduled Prolia injection
• Any symptoms of muscle cramping or perioral tingling since your last injection

Your prescriber may also want to document the discussion in your chart, particularly if your eGFR is already borderline, because any future creatinine rise will need that context to be interpreted correctly.

The European Medicines Agency's Prolia product information states that "denosumab can be used in patients with renal impairment without dose adjustment," but it separately advises that "patients with severe renal impairment are at greater risk of hypocalcemia" [12]. That guidance was written without creatine use in mind; your lab values need to reflect your actual kidney function, not a creatine-inflated creatinine.